AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02560168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computed tomographic coronary angiography
Description: Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
Study NCT02560168 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transthoracic Echocardiography
Study NCT03238417 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evidence-Based Quality Improvement
Description: Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
Study NCT04222543 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: RGD PET/CT
Description: Patients will receive an RGD PET/CT and a CT perfusion scan prior to treatment and during chemoradiotherapy
Study NCT02081989 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal denervation
Description: Renal denervation
Study NCT03908346 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid for Surrogate Decision Makers of Comatose Survivors of Cardiac Arrest
Description: a decision aid has been created that is a four page document meant to support surrogate decision makers for comatose survivors of cardiac arrest
Study NCT03821038 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CYT107
Description: IV twice a week at 10µg/kg for 3 weeks
Study NCT03821038 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: IV twice a week at the same volume for 3 weeks
Study NCT01192165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib (GSK1120212)
Description: Investigational small molecule targeted therapy (MEK1/2 inhibitor)
Study NCT01192165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chemotherapy
Study NCT01192165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Small molecule targeted therapy (EGFR inhibitor)
Study NCT01192165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy
Study NCT01192165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Chemotherapy
Study NCT01192165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: Chemotherapy
Study NCT01192165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy
Study NCT01952652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group N:Naproxen sodium
Description: drug will be given 60 minutes before surgery
Study NCT01952652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group NC :naproxen sodium codeine phosphate
Description: drug will be given 60 minutes before surgery
Study NCT00001566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: 3 syringes containing 1 x 10\^6peptide pulsed dendritic cells
Study NCT00001566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indinavir sulfate
Description: Oral dose, 350 mg/m\^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
Study NCT00001566 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Harvested autologous T cells, minimum dose 1 x 10\^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
Study NCT02779569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: decitabine
Study NCT02779569 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Study NCT01153919 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: romiplostim
Description: Given subcutaneously
Study NCT01153919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: Given orally
Study NCT01153919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ribavirin
Description: Given orally
Study NCT01153919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given subcutaneously
Study NCT01153919 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEG-interferon alfa-2a
Description: Given subcutaneously
Study NCT01153919 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PEG-interferon alfa-2a
Description: Given subcutaneously
Study NCT01153919 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01153919 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03622567 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Smartphone push notifications
Description: The purpose of this study is to assess how smartphone push notifications can impact the overall score, accuracy and reaction time of participants using the Brain Power Score application (app). Push notification quantity will be varied and counter-balanced.
Study NCT02051296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: RCT blinded placebo trial
Study NCT02051296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: RCT blinded placebo trial
Study NCT03449251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Vehicle
Study NCT03449251 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Verapamil
Description: NO independent challenge agent
Study NCT03449251 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: LN Monomethyl arginine
Description: Basal NO synthase inhibitor
Study NCT01258595 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-Dose Trivalent Inactivated Influenza Vaccine
Description: 0.5 mL Intramuscular
Study NCT01258595 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trivalent Inactivated Influenza Vaccine
Description: 0.5 mL, Intramuscular
Study NCT01215188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Aluminum-adjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2.2 mcg each), serotype 6B (4.4 mcg) and aluminum phosphate adjuvant (125 mcg) in each 0.5 mL dose.
Study NCT01215188 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V114 Non-adjuvanted
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose.
Study NCT01215188 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13®
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), serotype 6B (4.4 mcg each) and aluminum phosphate adjuvant (125 mcg) in each 0.5. mL dose.
Study NCT03452930 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo RT
Study NCT03452930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tinostamustine
Description: Given IV
Study NCT02643043 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biospecimen Collection
Description: Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
Study NCT03100487 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apple iPod Shuffle
Description: One session at least 5 days a week for a total of 8 weeks
Study NCT01548534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplementation with fish oil.
Description: Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
Study NCT01548534 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplementation with vegetable oil
Description: Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
Study NCT04584632 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Efemoral Vascular Scaffold System (EVSS)
Description: Balloon-expandable, bioresorbable vascular scaffolds coated with sirolimus
Study NCT00359879 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
Study NCT00359879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
Study NCT00566085 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Molecular Breast Imaging
Description: A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
Study NCT00033280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Study NCT00033280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00033280 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02607631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: treated with Pembrolizumab 200 mg every 3 weeks
Study NCT03900416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness App
Description: Mindfulness exercises will last 1-12 minutes. Each one asks participants to focus on something (e.g., breath, sounds, physical sensations) using guided instruction.
Study NCT02605655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMP-1915
Description: A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
Study NCT00915590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Custom eye drop eye three times a day in both eyes for a period of 6 weeks
Study NCT00915590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-1Ra
Description: 5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
Study NCT04836741 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micro Hand S robot
Description: The surgeries are performed with the Micro Hand S robot
Study NCT04836741 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscope
Description: The surgeries are performed with the laparoscope
Study NCT02631941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200 without oral activated charcoal
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler (Treatment A).
Study NCT02631941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler without oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation (Treatments B1 and B2 denote Symbicort without oral activated charcoal administered in two different periods).
Study NCT02631941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z7200 with oral activated charcoal
Description: 160 ug budesonide and 4.5 ug formoterol fumarate dihydrate, administered as two inhalations (2 x Z7200 capsules) of budesonide 80 ug/inhalation and formoterol 2.25 ug/inhalation, using an RS01 inhaler with a charcoal blockade (Treatment C).
Study NCT02631941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort Turbohaler with oral activated charcoal
Description: 320 ug budesonide and 9 ug formoterol fumarate dihydrate, administered as two inhalations of budesonide 160 ug/inhalation and formoterol 4.5 ug/inhalation from a Symbicort Turbohaler, with charcoal blockade (Treatment D).
Study NCT01225549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5423
Description: Suspension for nebulisation once daily 7 days
Study NCT01225549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide 200 microgram
Description: Dry powder for inhalation twice daily 7 days
Study NCT01225549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation once daily 7 days
Study NCT01225549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for nebulisation once daily 7 days
Study NCT01225549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Solution for nebulisation once daily 7 days
Study NCT00371735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorproguanil-dapsone-artesunate
Study NCT00371735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chlorproguanil-dapsone
Study NCT01297686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Karaoke Exercise
Description: lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
Study NCT01297686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance walking exercise
Description: Walking along a straight line on the ground, for 5 sets of 30 strides
Study NCT01297686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forefoot extension exercise
Description: The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
Study NCT01297686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standing one-legged balance exercise:
Description: This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
Study NCT01297686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ankle inversion/eversion exercise
Description: The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
Study NCT01297686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gastrocnemius and soleus stretching
Description: This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
Study NCT01297686 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gastrocnemius and soleus stretching
Description: This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
Study NCT01297686 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue-specific plantar fascia self massage
Description: This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
Study NCT01297686 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area.
Study NCT03101306 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR scans
Description: Additional imaging using MR scans.
Study NCT04974073 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: PHY606
Description: Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
Study NCT02605655 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Instant noodles without drug
Study NCT03507777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by OCT
Description: Stent implantation in high-risk or complex lesions in patients with coronary artery disease using OCT guidance
Study NCT03507777 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary PCI guided by Angiography
Description: Stent implantation in high-risk or complex lesions in patients with coronary artery disease using angiography guidance
Study NCT03507751 — intervention group
Intervention type: DRUG
Intervention: Meropenem
Description: 1.0 gram of meropenem given intravenously every 8 hours
Study NCT03507751 — intervention group
Intervention type: DEVICE
Intervention: CRRT
Description: Continuous renal replacement therapy for three days
Study NCT00473148 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BNP-guided weaning
Description: BNP-guided weaning
Study NCT00473148 — intervention group
Intervention type: PROCEDURE
Group type: NO_INTERVENTION
Intervention: Standard physician-directed weaning
Description: Standard physician-directed weaning
Study NCT02471105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preserved Bimatoprost 0.01%
Description: Eye drops solution Topical use Once in the evening 3 months
Study NCT02471105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafluprost Unit Dose Preservative Free 15microgram/ml
Description: Eye drops solution Topical use Once in the evening 3 months
Study NCT00992225 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY573636-sodium
Description: Dose is adjusted to target a specific maximum concentration (Cmax) based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
Study NCT03618043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028
Description: Starting dose 60mg,oral administered once daily.If tolerated subsequent cohorts will test increasing doses (120mg,180mg,240mg,320mg) of SH-1028.
Study NCT04974073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PHY606
Description: Danggui Buxue Tang is a well-known TCM formula indicated for anemia through immune modulation and increase energy metabolism
Study NCT01329198 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NeuroPace RNS® System Deep Brain Stimulator
Description: Utilizes a signal that the device detects and will respond to with an electrical pre-defined pulse if the signal is encountered.
Study NCT02349555 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Supplement Blend
Description: It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
Study NCT03212716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oseltamivir
Description: 150 mg twice a day during 10 days (ANSM guidelines for severe flu).
Study NCT03212716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oseltamivir
Description: 150 mg twice a day during 10 days (ANSM guidelines for severe flu).
Study NCT03212716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: 60 mgx3 per day during 10 days.
Study NCT03212716 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo of diltiazem